Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
| Autor: | Pavlina Jimbei, Valentin Cebotarescu, Gavin Cloherty, Lilia Cojuhari, Adalbert Krawczyk, Ulf Dittmer, Mark S. Anderson, Carina Elsner, Mary C. Kuhns, Vera Holzmayer, Jeff Gersch, Andrew Vaillant, Victor Pântea, Michel Bazinet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male HBsAg Time Factors Adolescent Hepatitis D Chronic Polymers viruses Medizin medicine.disease_cause Antiviral Agents Virus Polyethylene Glycols Young Adult Hepatitis B Chronic Pegylated interferon Nucleic Acids Medicine Humans lcsh:RC799-869 Seroconversion Hepatitis B Antibodies Hepatitis B virus Hepatitis B Surface Antigens Hepatology business.industry Coinfection virus diseases Alanine Transaminase Original Articles Hepatitis B biochemical phenomena metabolism and nutrition Middle Aged Moldova medicine.disease Virology digestive system diseases Treatment Outcome Tolerability DNA Viral lcsh:Diseases of the digestive system. Gastroenterology Original Article Female Interferons business medicine.drug |
| Zdroj: | Hepatology Communications Hepatology Communications, Vol 5, Iss 2, Pp 189-202 (2021) |
| Popis: | Finite therapy of HBV/HDV co‐infection with REP 2139‐Ca and pegIFN has good long term safety and is accompanied by high rates of functional cure of HDV, normalization of liver function and additional functional cure of HBV. HBV functional cure is accompanied inactivation / clearance of cccDNA and clearance of integrated HBV DNA. The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and hepatitis B surface antigen (HBsAg) loss/seroconversion in the REP 301 study (NCT02233075). The REP 301‐LTF study (NCT02876419) examined safety and efficacy during 3.5 years of follow‐up. In the current study, participants completing therapy in the REP 301 study were followed for 3.5 years. Primary outcomes were safety and tolerability, and secondary outcomes were HDV functional cure (HDV RNA target not detected [TND], normal alanine aminotransferase [ALT]), HBV virologic control (HBV DNA ≤2,000 IU/mL, normal ALT), HBV functional cure (HBV DNA TND; HBsAg |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|